EVOKE PHARMA, INC. Deferred Tax Assets, Valuation Allowance
EVOKE PHARMA, INC. had Deferred Tax Assets, Valuation Allowance of $28.23 million as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2025-03-13
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $28.23M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $28.94M; Deferred Tax Assets, Valuation Allowance as first filed $2.29M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $2.09M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $2.07M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2024-12-31 | $28.23M 10-K · filed 2025-03-13 | |
| 2023-12-31 | $28.94M 10-K · filed 2025-03-13 | $2.29M 10-K · filed 2024-03-14 |
| 2022-12-31 | $2.09M 10-K/A · filed 2024-05-14 | |
| 2021-12-31 | $2.07M 10-K · filed 2023-03-21 | |
| 2020-12-31 | $2.44M 10-K · filed 2022-03-08 | $2.00M 10-K · filed 2021-03-11 |
| 2019-12-31 | $1.16M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $899.00K 10-K · filed 2020-03-12 | |
| 2017-12-31 | $809.00K 10-K · filed 2019-03-06 | |
| 2016-12-31 | $870.00K 10-K · filed 2018-03-07 | |
| 2015-12-31 | $830.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $645.00K 10-K · filed 2016-03-10 | |
| 2013-12-31 | $437.00K 10-K · filed 2015-03-04 | |
| 2012-12-31 | $367.00K 10-K · filed 2014-03-25 |